UK Medicines and Healthcare products Regulatory Agency (MHRA)
-
UK’s MHRA approves pediatric EURneffy nasal spray for anaphylaxis
Anaphylaxis occurs when the immune system overreacts to a substance it perceives as harmful, triggering symptoms that can rapidly become life-threatening.
-
UK’s MHRA approves single-injection 7.2mg Wegovy pen for obesity management
The approval specifically applies to adults diagnosed with obesity and does not extend to individuals who are overweight with a BMI below 30kg/m² using Wegovy for weight management.
-
UK government commits USD4.8M to scale MHRA’s “AI Airlock” regulatory sandbox
Since launching in 2024, AI Airlock has grown steadily, moving beyond its initial pilot phase to tackle increasingly complex regulatory questions.
-
UK MHRA approves “triple-strength” Wegovy for obesity
Adults with obesity and a BMI of 30 kg/m² or higher can now use Wegovy at a 7.2mg dose level, which requires three consecutive 2.4mg doses instead of a single injection.
-
UK approves Gilead’s twice-yearly HIV prevention shot, Yeytuo
With this latest authorisation, individuals now have access to a long-acting option for prevention rather than daily pill-based regimens.
-
MHRA approves Roche’s Itovebi for advanced breast cancer treatment
This oral formulation offers a more convenient delivery method compared to intravenous treatments.